Skip to main content
Top
Published in: Radiation Oncology 1/2014

Open Access 01-12-2014 | Research

Optimal hypofractionated conformal radiotherapy for large brain metastases in patients with high risk factors: a single-institutional prospective study

Authors: Hiroshi K Inoue, Hiro Sato, Yoshiyuki Suzuki, Jun-ichi Saitoh, Shin-ei Noda, Ken-ichi Seto, Kota Torikai, Hideyuki Sakurai, Takashi Nakano

Published in: Radiation Oncology | Issue 1/2014

Login to get access

Abstract

Background

A single-institutional prospective study of optimal hypofractionated conformal radiotherapy for large brain metastases with high risk factors was performed based on the risk prediction of radiation-related complications.

Methods

Eighty-eight patients with large brain metastases ≥10 cm3 in critical areas treated from January 2010 to February 2014 using the CyberKnife were evaluated. The optimal dose and number of fractions were determined based on the surrounding brain volume circumscribed with a single dose equivalent (SDE) of 14 Gy (V14) to be less than 7 cm3 for individual lesions. Univariate and multivariate analyses were conducted.

Results

As a result of optimal treatment, 92 tumors ranging from 10 to 74.6 cm3 (median, 16.2 cm3) in volume were treated with a median prescribed isodose of 57% and a median fraction number of five. In order to compare the results according to the tumor volume, the tumors were divided into the following three groups: 1) 10–19.9 cm3, 2) 20–29.9 cm3 and 3) ≥30 cm3. The lesions were treated with a median prescribed isodose of 57%, 56% and 55%, respectively, and the median fraction number was five in all three groups. However, all tumors ≥20 cm3 were treated with ≥ five fractions. The median SDE of the maximum dose in the three groups was 47.2 Gy, 48.5 Gy and 46.5 Gy, respectively. Local tumor control was obtained in 90.2% of the patients, and the median survival was nine months, with a median follow-up period of seven months (range, 3-41 months). There were no significant differences in the survival rates among the three groups. Six tumors exhibited marginal recurrence 7-36 months after treatment. Ten patients developed symptomatic brain edema or recurrence of pre-existing edema, seven of whom required osmo-steroid therapy. No patients developed radiation necrosis requiring surgical resection.

Conclusion

Our findings demonstrate that the administration of optimal hypofractionated conformal radiotherapy based on the dose-volume prediction of complications (risk line for hypofractionation), as well as Kjellberg’s necrosis risk line used in single-session radiosurgery, is effective and safe for large brain metastases or other lesions in critical areas.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009, 10: 1037-1044. 10.1016/S1470-2045(09)70263-3.CrossRefPubMed Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009, 10: 1037-1044. 10.1016/S1470-2045(09)70263-3.CrossRefPubMed
2.
go back to reference Lee CC, Yen CP, Xu Z, Schlesinger D, Sheehan J: Large intracranial metastatic tumors treated by Gamma Knife surgery: outcomes and prognostic factors. J Neurosurg. 2014, 120: 52-59. 10.3171/2013.9.JNS131163.CrossRefPubMed Lee CC, Yen CP, Xu Z, Schlesinger D, Sheehan J: Large intracranial metastatic tumors treated by Gamma Knife surgery: outcomes and prognostic factors. J Neurosurg. 2014, 120: 52-59. 10.3171/2013.9.JNS131163.CrossRefPubMed
3.
go back to reference Aoyama H, Shirato H, Onimaru R, Kagei K, Ikeda J, Ishii N, Sawamura Y, Miyasaka K: Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull. Int J Radiat Oncol Biol Phys. 2003, 56: 793-800. 10.1016/S0360-3016(03)00014-2.CrossRefPubMed Aoyama H, Shirato H, Onimaru R, Kagei K, Ikeda J, Ishii N, Sawamura Y, Miyasaka K: Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull. Int J Radiat Oncol Biol Phys. 2003, 56: 793-800. 10.1016/S0360-3016(03)00014-2.CrossRefPubMed
4.
go back to reference Lindvall P, Bergström P, Löfroth PO, Henriksson R, Bergenheim AT: Hypofractionated conformal stereotactic radiotherapy alone or in combination with whole-brain radiotherapy in patients with cerebral metastases. Int J Radiat Oncol Biol Phys. 2005, 61: 1460-1466. 10.1016/j.ijrobp.2004.08.027.CrossRefPubMed Lindvall P, Bergström P, Löfroth PO, Henriksson R, Bergenheim AT: Hypofractionated conformal stereotactic radiotherapy alone or in combination with whole-brain radiotherapy in patients with cerebral metastases. Int J Radiat Oncol Biol Phys. 2005, 61: 1460-1466. 10.1016/j.ijrobp.2004.08.027.CrossRefPubMed
5.
go back to reference Marchetti M, Milanesi I, Falcone C, De Santis M, Fumagalli L, Brait L, Bianchi L, Fariselli L: Hypofractionated stereotactic radiotherapy for oligometastases in the brain: a single-institution experience. Neurol Sci. 2011, 32: 393-399. 10.1007/s10072-010-0473-4.CrossRefPubMed Marchetti M, Milanesi I, Falcone C, De Santis M, Fumagalli L, Brait L, Bianchi L, Fariselli L: Hypofractionated stereotactic radiotherapy for oligometastases in the brain: a single-institution experience. Neurol Sci. 2011, 32: 393-399. 10.1007/s10072-010-0473-4.CrossRefPubMed
6.
go back to reference Ogura K, Mizowaki T, Ogura M, Sakanaka K, Arakawa Y, Miyamoto S, Hiraoka M: Outcomes of hypofractionated stereotactic radiotherapy for metastatic brain tumors with high risk factors. J Neurooncol. 2012, 109: 425-432. 10.1007/s11060-012-0912-6.CrossRefPubMed Ogura K, Mizowaki T, Ogura M, Sakanaka K, Arakawa Y, Miyamoto S, Hiraoka M: Outcomes of hypofractionated stereotactic radiotherapy for metastatic brain tumors with high risk factors. J Neurooncol. 2012, 109: 425-432. 10.1007/s11060-012-0912-6.CrossRefPubMed
7.
go back to reference Märtens B, Janssen S, Werner M, Frühauf J, Christiansen H, Bremer M, Steinmann D: Hypofractionated stereotactic radiotherapy of limited brain metastases: a single-centre individualized treatment approach. BMC Cancer. 2012, 12: 497-10.1186/1471-2407-12-497.PubMedCentralCrossRefPubMed Märtens B, Janssen S, Werner M, Frühauf J, Christiansen H, Bremer M, Steinmann D: Hypofractionated stereotactic radiotherapy of limited brain metastases: a single-centre individualized treatment approach. BMC Cancer. 2012, 12: 497-10.1186/1471-2407-12-497.PubMedCentralCrossRefPubMed
8.
go back to reference Eaton BR, Gebhardt B, Prabhu R, Shu HK, Curran WJ, Crocker I: Hypofractionated radiosurgery for intact or resected brain metastases: defining the optimal dose and fractionation. Radiat Oncol. 2013, 8: 135-10.1186/1748-717X-8-135.PubMedCentralCrossRefPubMed Eaton BR, Gebhardt B, Prabhu R, Shu HK, Curran WJ, Crocker I: Hypofractionated radiosurgery for intact or resected brain metastases: defining the optimal dose and fractionation. Radiat Oncol. 2013, 8: 135-10.1186/1748-717X-8-135.PubMedCentralCrossRefPubMed
9.
go back to reference Inoue HK, Sato H, Seto K, Torikai K, Suzuki Y, Saitoh J, Noda SE, Nakano T: Five-fraction CyberKnife radiotherapy for large brain metastases in critical areas: impact on the surrounding brain volumes circumscribed with a single dose equivalence of 14 Gy (V14) to avoid radiation necrosis. J Radiat Res. 2014, 55: 334-342. 10.1093/jrr/rrt127.PubMedCentralCrossRefPubMed Inoue HK, Sato H, Seto K, Torikai K, Suzuki Y, Saitoh J, Noda SE, Nakano T: Five-fraction CyberKnife radiotherapy for large brain metastases in critical areas: impact on the surrounding brain volumes circumscribed with a single dose equivalence of 14 Gy (V14) to avoid radiation necrosis. J Radiat Res. 2014, 55: 334-342. 10.1093/jrr/rrt127.PubMedCentralCrossRefPubMed
10.
go back to reference Inoue HK, Sato H, Suzuki Y, Saitoh J, Noda S, Seto K, Torikai K, Nakano T: Dose-volume prediction of radiation-related complications after hypofractionated conformal radiotherapy for brain metastases in critical areas. Cureus. 2014, 6 (7): e189-doi:10.7759/cureus.189 Inoue HK, Sato H, Suzuki Y, Saitoh J, Noda S, Seto K, Torikai K, Nakano T: Dose-volume prediction of radiation-related complications after hypofractionated conformal radiotherapy for brain metastases in critical areas. Cureus. 2014, 6 (7): e189-doi:10.7759/cureus.189
11.
go back to reference Barker FG, Butler WE, Lyons S, Cascio E, Ogilvy CS, Loeffler JS, Chapman PH: Dose-volume prediction of radiation-related complications after proton beam radiosurgery for cerebral arteriovenous malformations. J Neurosurg. 2003, 99: 254-263. 10.3171/jns.2003.99.2.0254.CrossRefPubMed Barker FG, Butler WE, Lyons S, Cascio E, Ogilvy CS, Loeffler JS, Chapman PH: Dose-volume prediction of radiation-related complications after proton beam radiosurgery for cerebral arteriovenous malformations. J Neurosurg. 2003, 99: 254-263. 10.3171/jns.2003.99.2.0254.CrossRefPubMed
12.
go back to reference Park C, Papiez L, Zhang S, Story M, Timmerman RD: Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008, 70: 847-852. 10.1016/j.ijrobp.2007.10.059.CrossRefPubMed Park C, Papiez L, Zhang S, Story M, Timmerman RD: Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008, 70: 847-852. 10.1016/j.ijrobp.2007.10.059.CrossRefPubMed
13.
go back to reference Timmerman RD: An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008, 18: 215-222. 10.1016/j.semradonc.2008.04.001.CrossRefPubMed Timmerman RD: An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008, 18: 215-222. 10.1016/j.semradonc.2008.04.001.CrossRefPubMed
14.
go back to reference Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997, 37: 745-751. 10.1016/S0360-3016(96)00619-0.CrossRefPubMed Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997, 37: 745-751. 10.1016/S0360-3016(96)00619-0.CrossRefPubMed
15.
go back to reference Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004, 363: 1665-1672. 10.1016/S0140-6736(04)16250-8.CrossRefPubMed Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004, 363: 1665-1672. 10.1016/S0140-6736(04)16250-8.CrossRefPubMed
16.
go back to reference Williams BJ, Suki D, Fox BD, Pelloski CE, Maldaun MV, Sawaya RE, Lang FF, Rao G: Stereotactic radiosurgery for metastatic brain tumors: a comprehensive review of complications. J Neurosurg. 2009, 111: 439-448. 10.3171/2008.11.JNS08984.CrossRefPubMed Williams BJ, Suki D, Fox BD, Pelloski CE, Maldaun MV, Sawaya RE, Lang FF, Rao G: Stereotactic radiosurgery for metastatic brain tumors: a comprehensive review of complications. J Neurosurg. 2009, 111: 439-448. 10.3171/2008.11.JNS08984.CrossRefPubMed
17.
go back to reference Inoue HK: Low-dose radiosurgery for large vestibular schwannomas: long-term results of functional preservation. J Neurosurg. 2005, 102 (Suppl): 111-113. 10.3171/jns.2005.102.s_supplement.0111.CrossRefPubMed Inoue HK: Low-dose radiosurgery for large vestibular schwannomas: long-term results of functional preservation. J Neurosurg. 2005, 102 (Suppl): 111-113. 10.3171/jns.2005.102.s_supplement.0111.CrossRefPubMed
18.
go back to reference Inoue HK: Long-term results of Gamma Knife surgery for arteriovenous malformations: 10- to 15-year follow up in patients treated with lower doses. J Neurosurg. 2006, 105 (Suppl): 64-68.PubMed Inoue HK: Long-term results of Gamma Knife surgery for arteriovenous malformations: 10- to 15-year follow up in patients treated with lower doses. J Neurosurg. 2006, 105 (Suppl): 64-68.PubMed
Metadata
Title
Optimal hypofractionated conformal radiotherapy for large brain metastases in patients with high risk factors: a single-institutional prospective study
Authors
Hiroshi K Inoue
Hiro Sato
Yoshiyuki Suzuki
Jun-ichi Saitoh
Shin-ei Noda
Ken-ichi Seto
Kota Torikai
Hideyuki Sakurai
Takashi Nakano
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2014
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-014-0231-5

Other articles of this Issue 1/2014

Radiation Oncology 1/2014 Go to the issue